F-labeled Ab-selective radioligands (Rowe and Villemagne, 2013) , resulting in the approval of one of these 18 F-labeled agents (Amyvid) by the U.S. Food and Drug Administration for clinical use as an Ab plaque imaging agent. What has been missing from the research scene, until very recently, is the availability of a tau-selective PET radioligand to track tau deposits in AD and other clinical syndromes neuropathologically classified as tauopathies (Spillantini and Goedert, 2013) . Because the occurrence of Ab plaques and NFTs overlap in many brain regions in AD, PET radioligands with good selectivity for Ab or tau are necessary to accurately assess the relative concentration of each protein.
Nonselective PET radioligands, such as [ 18 F]FDDNP (Shin et al., 2011) , bind to both Ab plaques and NFTs, and accurate quantitation of the amount of each protein present in many brain regions is not achievable. Hence, the field has sought to develop tau-selective PET radioligands that would complement existing Ab-selective PET radioligands to image AD, as well as presymptomatic AD subjects (Morris et al., 2010; Sperling et al., 2011) . Such an agent would likely prove useful in following the clinical progression of AD, because NFT concentrations appear to reflect severity of clinical symptoms (Nagy et al., 1995) , while Ab plaques appear at an early (presymptomatic) stage and level off relatively early in the disease process (Hyman et al., 1993 ). An important use of tau-selective PET radiopharmaceuticals will be to assess tau load (or the loss or absence of tau load) in anti-tau or anti-Ab therapeutic clinical trials. Several clinical trials are under way to test the Ab-cascade hypothesis in Ab-positive cognitively normal subjects, and the addition of a tau-selective PET radioligand to Ab-selective radioligands in these trials would provide additional important insights into the pathophysiology of AD.
A tau-selective PET radioligand could potentially prove extremely useful in non-AD tauopathies as well. These include neurodegenerative diseases such as frontal temporal lobar degeneration (FTLD), Pick's disease, corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP). In their pure form, these dementias are characterized by tau deposits without the co-occurrence of Ab plaques. It is important to note that tau deposits are of variable composition across these diseases. In AD, there are six different isoforms of hyperphosphorylated tau (varying in size from 352 to 441 amino acids). Three of the tau isoforms possess a three-repeat region, while three isoforms possess a four-repeat region. These repeat regions are believed to be responsible for the extended b-pleated sheet (amyloid) nature of these tau deposits. The various non-AD tauopathies contain differing combinations of these isoforms. If a tauselective PET radioligand bound to all types of tau deposits, regardless of the combination of isoforms, it would find additional important uses in imaging the non-AD tauopathies. However, it is possible that a radioligand might bind well only to three-repeat tau isoforms and not be effective in imaging other tauopathies comprised mainly of fourrepeat isoforms. For this reason, it is critical to assess the binding properties of the tau-selective radioligand to a variety of tau isoforms.
Previous progress in the development of tau-selective PET radioligands has been reported recently by two different groups: the Tohoku University/Austin Hospital Melbourne group have reported a series of 18 F-labeled THK compounds Okamura et al., 2013) and the Siemens/Lilly group have reported the 18 F-labeled T807 and T808 compounds (Chien et al., 2013a (Chien et al., , 2013b . Both groups have focused initially upon the binding of their tau-selective radioligands in AD brain, and little information regarding binding properties of these radioligands to the non-AD tauopathies has been reported to date. In this issue of Neuron, Maruyama et al. (2013) describe the in vitro and in vivo properties of a new class of selective tau-binding ligands they term PBBs. Some of the PBB ligands fluoresce and were used in in vitro assays and in vivo optical imaging studies in a transgenic tauopathy mouse model, while the most promising PBB ligand (termed PBB3) was radiolabeled with 11 C and used in PET imaging studies in the tauopathy mouse model and in elderly cognitively normal, AD, and CBD subjects (a four-repeat predominant tauopathy).
There are advantages and disadvantages with the choice of 11 C versus 18 F radiolabels. The longer half-life of 18 F (109.8 min) permits the regional distribution of the radiopharmaceutical from a central nuclear pharmacy production center and provides generally more convenient PET imaging logistics relative to the shorter half-life 11 C (20.4 min) radionuclide. However for research imaging purposes, the 11 C radiolabel permits two or more serial PET studies to be conducted in the same subject with different radiopharmaceuticals on the same day several hours apart. Maruyama et al. (2013) screened a number of fluorescent compounds for selective binding of the ligands to tau deposits (from both AD and non-AD tauopathies) over Ab plaques. They found that compounds with extended conjugated backbones with a core length of 15-18 Å bound most favorably to tau. The conjugated butadiene linkage between the two aromatic ring systems of PBBs apparently provides the basis for their high tau binding affinities. It is interesting to note the structural similarities between PiB and PBB3 (Figure 1 ), yet their binding affinities to aggregated Ab and tau are very different. Just as surprising is the difference in selectivity between PBB1 (which also binds Ab plaques) and PBB3 (Figure 1 ) on tissue sectionsalthough large differences in lipophilicity may account for this.
In vitro and ex vivo fluorescence imaging of tau inclusions with PBBs utilized PS19 transgenic mice expressing a FTDP-17 four-repeat tau isoform with the P301S mutation, and tau deposits were apparent in the brain stem and spinal cord of these mice. Other fluorescence imaging experiments were conducted in a second mouse model of tauopathy (rTg4510 mice expressing the FTDP-17 four-repeat P301L mutation), and these mice demonstrated specific binding of PBBs to neuronal tau inclusions in the neocortex and hippocampus. In addition, several PPBs were radiolabeled with 11 C and examined in these mice after intravenous injection using ex vivo autoradiographic analysis and microPET imaging. PBB3 in neocortical and subcortical regions. This is the first reported apparently successful PET imaging study of tau deposits in a non-AD four-repeat predominant tauopathy using a tau-selective radiopharmaceutical. Overall, the PBB3 tau imaging results presented by Maruyama et al. (2013) are highly encouraging and provide strong support for the tau-selective binding of the ligand to tau deposits in two FTDP-17 transgenic mouse models and in vivo in AD and CBD subjects. The pharmacokinetic properties of the radioligand are generally favorable, with rapid brain uptake, relatively fast clearance of tracer from brain regions containing low tau loads, reversible specific binding of the tracer in tau-containing brain regions, and the absence of lipophilic radiolabeled metabolites in the blood. However, several issues remain to be explored and further evaluated in future imaging studies using this tracer, including (1) the basis of the relatively high retention of the tracer in the dural venous sinuses of human subjects; (2) binding and imaging data in three-repeat predominant tau isoform cases such as Pick's disease; (3) the practical impact of the relatively low specific signal of [ 11 C]PBB3 in brain regions of high tau load (only 1.5 SUVR units) with respect to detection sensitivity limits in a variety of subjects; (4) thorough pharmacokinetic analyses of the radioligand in control, probable AD, and threeand four-repeat non-AD tauopathies; (5) The subventricular zone (SVZ) continuously supplies new interneurons that incorporate into pre-existing olfactory bulb circuitry. Khodosevich et al. (2013) show that connective tissue growth factor (CTGF) regulates a multicellular signaling cascade determining the number of postnatally born inhibitory interneurons in odoractivated glomeruli.
Robust neurogenesis takes place in the subventricular zone (SVZ) of the adult mouse brain (Luskin, 1993) . The neuroblasts, generated in the SVZ, travel along the rostral migratory stream, arrive at the core of the olfactory bulb (OB), and migrate radially until their appearance in either the granule cell layer or the glomerular layer (Lois and Alvarez-Buylla, 1994; Luskin, 1993) . Subsequently, the neuroblasts differentiate in their respective layers into the two major interneurons: granule cells and periglomerular cells. Each day, thousands of neuroblasts migrate to the OB and integrate into preexisting circuits after differentiating. The majority end up in the granule layer, while the rest end their journey in the glomerular layer based on their fate that was established in the SVZ (Luskin, 1993; Merkle et al., 2007) . This continual flux of cells provides the substrate to selectively incorporate new cells and remodel the olfactory circuitry that processes sensory input. In this issue of Neuron, Khodosevich et al. (2013) show that odorant-activated expression of the previously characterized connective tissue growth factor, CTGF, controls the survival of periglomerular cells by potentiating TGFb2 activity and activating an apoptotic pathway in periglomerular cells in selective glomeruli.
